Psychostimulants in moderate to severe affective disorder: A systematic review of randomized controlled trials

Nordic Journal of Psychiatry

Volumn 67, Issue 6, 2013, Pages 369-382

  Abbasowa, Leda ^a   Kessing, Lars V ^b   Vinberg, Maj ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Affective disorder; Major depression; Psychostimulants; Randomized controlled trials

Indexed keywords

AMPHETAMINE; ARMODAFINIL; DEXAMPHETAMINE; FLUOXETINE; METHAMPHETAMINE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; PEMOLINE; PHENELZINE; PLACEBO; PSYCHOSTIMULANT AGENT; SERTRALINE;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL PRACTICE; DAYTIME SOMNOLENCE; DEPRESSION; DRUG SUBSTITUTION; FOLLOW UP; GABAERGIC TRANSMISSION; HAMILTON SCALE; HUMAN; LIVER TOXICITY; MAJOR DEPRESSION; MONOTHERAPY; MOOD DISORDER; NARCOLEPSY; REVIEW; SLEEP DISORDERED BREATHING; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADULT; AGED; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84887984804     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2012.752035     Document Type: Review

References (65)

1. Investigating in mental health. World Health Organization 2003; 3-48.
2. Connoly KR and Thase ME. If at fi rst you don't succeed: A review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011;71:43-64.
3. Tranter R, O'Donovan C, Chandarana P, Kennedy S. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002;27:241-7.
4. Fava M. Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol 2006;20:29-34.
5. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al. Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Dis 1998;50:97-108.
6. Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatr y 2000;61 Suppl 2:20-5.
7. Papakostas GI. Managing partial response or nonresponse: Switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009;70:16-25.
8. Linet LS. Treatment of a refractory depression with a combination of fl uoxetine and d -amphetamine. Am J Psychiatry 1989;146:803-4.
9. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: A case series. J Clin Psychiatry 1996;57:72-6.
10. Feighner JP, Herbstein J, Damloujii N. Combined MAOI, TCA and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry 1985;46:206-9.
11. Fawcett J, Kravitz HM, Zajeca JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991;11:127-32.
12. Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriatr Psychiatry 2001;9:298-303.
13. Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second generation antidepressants: A case series. Depress Anxiety 1998;7:89-91.
14. Menza MA, Kaufman KR, Castellanos A. Modafi nil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000;61:378-81.
15. Konuk N, Atasoy N, Atik L, Akay O. Open-label study of adjunct modafi nil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors. Adv Ther 2006;23:646-54.
16. Rasmussen NA, Schrøder P, Olsen LR, Brødsgaard M, Undén M, Bech P. Modafinil augmentation in depressed patients with partial response to antidepressants: A pilot study on self-reported symptoms covered by the major depression inventory (MDI) and the symptom checklist (SCL-92). Nord J Psychiatry 2005;59:173-8.
17. Orr K and Taylor D. Psychostimulants in the treatment of depression: A review of the evidence. CNS Drugs 2007;21:239-57.
18. DeBattista C and Lembke A. Update on augmentation of antidepressant response in resistant depression. Curr Psychiatry Rep 2005;7:435-40.
19. Wallace LJ. Effects of amphetamine on subcellular distribution of dopamine and DOPAC. Synapse 2012 [Epub ahead of print].
20. Berridge CW and Devilbiss DM. Psychostimulants as cognitive enhancers: The prefrontal cortex, catecholamines, and attentiondefi cit/hyperactivity disorder. Biol Psychiatry 2011;69:e101-e111.
21. Markowitz JS and Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-defi cit hyperactivity disorder. Clin Pharmacokinet 2001;40:753-72.
22. Etwel FA, Rieder MJ, Bend JR, Koren G. A surveillance method for the early identifi cation of idiosyncratic adverse drug reactions. Drug Safety 2008;31:169-80.
23. Minzenberg MJ and Carter CS. Modafi nil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008;33:1477-502.
24. Kumar R. Approved and investigational uses of modafi nil: An evidence-based review. Drugs 2008;68:1803-39.
25. DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR. Adjunct modafi nil for the short-term treatment of fatigue and s leepiness in patients with major depressive disorder: A preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003;64:1057-64.
26. Dunlop BW, Crits-Christoph P, Evans DL, Hirschowitz J, Solvason HB, Rickels K, et al. Coadministration of modafi nil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: A double-blind, placebo-controlled study. J Clin Psychopharmacol 2007;27:614-19.
27. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafi nil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005;66:85-93.
28. Abolfazli R, Hosseini M, Ghanizadeh A, Ghaleiha A, Tabrizi M, Raznahan M, et al. Double-blind randomized parallel-group clinical trial of effi cacy of the combination fl uoxetine plus modafi nil versus fl uoxetine plus placebo in the treatment of major depression. Depress Anxiety 2011;28:297-302.
29. Beck J, Hemmeter U, Brand S, Muheim F, Hatzinger M, Holsboer-Trachsler E. Modafi nil reduces microsleep during partial sleep deprivation in depressed patients. J Psychiatr Res. 2010;44:853-64.
30. Vaishnavi S, Gadde K, Alamy S, Zhang W, Connor K, Davidson JRT. Modafi nil for atypical depression: Effects of open-label and double-blind discontinuation treatment. J Clin Psychopharmacol 2006;26:373-8.
31. Patkar AA, Masand PS, Pae C, Peindl K, Hooper-Wood C, Mannelli P, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 2006;26:653-6.
32. Ravindran AV, Kennedy SH, O'Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-relase oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: Results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2008;69:87-94.
33. Postolache TT, Rosenthal RN, Hellerstein DJ, Aromin R, Kelton GM, Muran JC, et al. Early augmentation of sertraline with methylphenidate. J Clin Psychiatry 1999;2:123-4.
34. Little KY. d -Amphetamine versus methylphenidate effects in depressed inpatients. J Clin Psychiatry 1993;54:349-55.
35. Hare EH, Dominian J, Sharpe L. Phenelzine and dexamphetamine in depressive illness: A comparative trial. Br Med J 1962;1:9-12.
36. Hare EH, McCance C, McCormick WO. Imipramine and " Drinamyl " in depressive illness: A comparative trial. Br Med J 1964;1:818-20.
37. Cookson J, Silverstone T. The effects of methylamphetamine on mood and appetite in depressed patients: A placebo-controlled study. Int Clin Psychopharmacol 1986;1:127-33.
38. Elizur A, Wintner I, Davidson S. The clinical and psychological effects of pemoline in depressed patients - A controlled study. Int Pharmacopsychiatry 1979;14:127-34.
39. Frye MA, Grunze H, Suppes T, McElroy SL, Keck PE, Walden J, et al. A placebo-controlled evaluation of adjunctive modafi nil in the treatment of bipolar depression. Am J Psychiatry 2007;164:1242-9.
40. Calabrese JR, Ketter TA, Youakim JM, Tiller JM, Yang R, Frye MA. Adjunctive armodafi nil for major depressive episodes associated with bipolar I disorder: A randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J Clin Psychiatry 2010;71:1363-70.
41. Silberman EK, Reus VI, Jimerson DC, Lynott AM, Post RM. Heterogeneity of amphetamine response in depressed patients. Am J Psychiatry 1981;10:1302-7.
42. Reus VI, Silberman EK, Post RM, Weingartner H. d-Amphetamine: Effects on memory in a depressed population. Biol Psychiatry 1979;14:345-56.
43. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-defi cit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128:1007-22.
44. Sills TL, Greenshaw AJ, Baker GB, Fletcher PJ. Subchronic fluoxetine treatment induces a transient potentiation of amphetamine- induced hyperlocomotion: Possible pharmacokinetic interaction. Behav Pharmacol 2000;11:109-16.
45. Sills TL, Greenshaw AJ, Baker GB, Fletcher PJ. Acute fl uoxetine treatment potentiates amphetamine hyperactivity and amphetamine-induced nucleus accumbens dopamine release: Possible pharmacokinetic interaction. Psychopharmacology 1999;141:421-7.
46. Sills TL, Greenshaw AJ, Baker GB, Fletcher PJ. The potentiating effect of sertraline and fl uoxetine on amphetamine-induced locomotor activity is not mediated by serotonin. Psychopharmacology 1999;143:426-32.
47. Ferraro L, Fuxe K, Agnati L, Tanganelli S, Tomasini MC, Antonelli T. Modafi nil enhances the increase of extracellular serotonin levels induced by the antidepressant drugs fl uoxetine and imipramine: A dual probe microdialysis study in awake rat. Synapse 2005;55:230-41.
48. Ramaswamy S, Mattai A, Wilson DR. Modafi nil: Not just for sleep disorders? Curr Psychiatry 2007;6:67-79.
49. Videbech P. Modafi nil in the treatment of depression: A systematic review. Ugeskr Laeger 2012;174:348-51.
50. Lam JY, Freeman MK, Cates ME. Modafi nil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants. Ann Pharmacother 2007;41:1005-12.
51. Ninan PT, Hassman HA, Glass SJ, McManus FC. Adjunctive modafi nil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J Clin Psychiatry 2004;65:414-20.
52. DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. A prospective trial of modafi nil as an adjunctive treatment of major depression. J Clin Psychopharmacol 2004;24:87-90.
53. Markovitz PJ and Wagner S. An open-label trial of modafi nil augmentation in patients with partial response to antidepressant therapy. J Clin Psychopharmacol 2003;23:207-9.
54. Price CS and Taylor FB. A retrospective chart review of the effects of modafi nil on depression as monotherapy and as adjunctive therapy. Depress Anxiety 2005;21:149-53.
55. Kaufman KR, Menza MA, Fitzsimmons A. Modafi nil monotherapy in depression. Eur Psychiatry 2002;17:167-9.
56. Fava M, Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ. Modafi nil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry 2007;19:153-9.
57. Candy M, Jones L, Williams R, Tookman A, King M. Psychostimulants for depression. Cochrane Database Syst Rev 2008 (2):CD006722.
58. www.clinicaltrial.gov.
59. Garvey MJ, Hwang S, Teubner-Rhodes D, Zander J, Rhem C. 0 Dextroamphetamine treatment of mania. J Clin Psychiatry 1987;48:412-13.
60. Bschor T, Muller-Oerlinghausen B, Ulrich G. Decreased level of EEG-vigilance in acute mania as a possible predictor for a rapid effect of methylphenidate: A case study. Clin Electroencephalogr 2001;32:36-9.
61. Beckmann H, Heinemann H. d-Amphetamine in manic syndrome. Drug Research 1976;26:1185-6.
62. Brown WA, Mueller B. Alleviation of manic symptoms with catecholamine agonists. Am J Psychiatry 1979;136:230-1.
63. Janowsky DS, El-Yousel MK, Davis JM, Sekerke HJ. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 1973;28:185-91.
64. Schoenknecht P, Olbrich S, Sander C, Spindler P, Hegerl U. Treatment of acute mania with modafi nil monotherapy. Biol Psychiatry 2010;67:e55-e57.
65. Hegerl U, Sander C, Olbrich P, Schoenknecht P. Are psychostimulants a treatment option in mania? Pharmacopsychiatry 2009;42:169-74.